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A novel mechanism of regulating breast cancer
cell migration via palmitoylation-dependent
alterations in the lipid raft affiliation of CD44
Irina S Babina, Elaine A McSherry, Simona Donatello, Arnold DK Hill and Ann M Hopkins*
Abstract
Introduction: Most breast cancer-related deaths result from metastasis, a process involving dynamic regulation of
tumour cell adhesion and migration. The adhesion protein CD44, a key regulator of cell migration, is enriched in
cholesterol-enriched membrane microdomains termed lipid rafts. We recently reported that raft affiliation of CD44
negatively regulates interactions with its migratory binding partner ezrin. Since raft affiliation is regulated by
post-translational modifications including palmitoylation, we sought to establish the contribution of CD44 palmitoylation
and lipid raft affiliation to cell migration.
Methods: Recovery of CD44 and its binding partners from raft versus non-raft membrane microdomains was profiled in
non-migrating and migrating breast cancer cell lines. Site-directed mutagenesis was used to introduce single or double
point mutations into both CD44 palmitoylation sites (Cys286 and Cys295), whereupon the implications for lipid raft
recovery, phenotype, ezrin co-precipitation and migratory behaviour was assessed. Finally CD44 palmitoylation
status and lipid raft affiliation was assessed in primary cultures from a small panel of breast cancer patients.
Results: CD44 raft affiliation was increased during migration of non-invasive breast cell lines, but decreased
during migration of highly-invasive breast cells. The latter was paralleled by increased CD44 recovery in non-raft
fractions, and exclusive non-raft recovery of its binding partners. Point mutation of CD44 palmitoylation sites reduced
CD44 raft affiliation in invasive MDA-MB-231 cells, increased CD44-ezrin co-precipitation and accordingly enhanced cell
migration. Expression of palmitoylation-impaired (raft-excluded) CD44 mutants in non-invasive MCF-10a cells was
sufficient to reversibly induce the phenotypic appearance of epithelial-to-mesenchymal transition and to increase
cell motility. Interestingly, cell migration was associated with temporal reductions in CD44 palmitoylation in wild-type
breast cells. Finally, the relevance of these findings is underscored by the fact that levels of palmitoylated CD44 were
lower in primary cultures from invasive ductal carcinomas relative to non-tumour tissue, while CD44 co-localisation with
a lipid raft marker was less in invasive ductal carcinoma relative to ductal carcinoma in situ cultures.
Conclusion: Our results support a novel mechanism whereby CD44 palmitoylation and consequent lipid raft affiliation
inversely regulate breast cancer cell migration, and may act as a new therapeutic target in breast cancer metastasis.
Introduction
Despite improvements in screening and care, breast can-
cer remains a leading cause of death in women world-
wide [1]. Most breast cancer-related deaths arise from
tumour metastasis to secondary sites. Cell migration out
of the primary tumour is one of the earliest events in
the metastatic cascade, and requires coordinated activa-
tion of numerous cell adhesion signalling cascades.
CD44 is an important cell adhesion molecule with a var-
iety of tissue-dependent functions [2]. CD44 is the major
receptor for the extracellular matrix component hyaluro-
nan [3], can act as a co-receptor for growth factors [4]
and can organise the actin cytoskeleton through a range
of cytoplasmic linker proteins [5]. Because CD44 is in-
volved in a wide spectrum of physiological functions, its
dysregulation has been implicated in progression of a
variety of cancers [6], including breast cancer. Import-
antly, CD44 expression has been reported to be elevated
in triple-negative mammary tumours and to associate
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with poor patient outcome [7]. Paradoxically, however,
CD44 has been described as a tumour suppressor in
some other cancers [8,9]. Some studies attribute this dis-
crepancy to cell-type dependence and differential CD44
subcellular localisation patterns [10,11]. Consequently,
in this manuscript we specifically investigate whether
regulation of the subcellular localisation of CD44 could
account for its regulation of breast cancer cell migration
(an early event in the metastatic cascade).
Palmitoylation of two CD44 cysteine residues at positions
286 and 295 in the transmembrane and juxta-membrane
regions confers high affinity for cholesterol-enriched
and sphingolipid-enriched regions of the cell mem-
brane, termed lipid rafts [11]. Rafts are dynamic mem-
brane regions that cluster together components of
many signalling cascades known to be altered in cancer
[12,13]. The CD44 cytoplasmic tail helps organise the
actin cytoskeleton via cytoplasmic actin-binding linker
proteins, including members of the ezrin/radixin/moesin
family, merlin, annexin II and ankyrin. The intrinsic role
of actin reorganisation in cellular adhesion and migration
underlies why dysregulation of CD44-based signalling has
been associated with the pathophysiological manifesta-
tions of cancer dissemination and metastasis [14,15].
However, the specific contribution of lipid rafts to the
regulation of CD44-dependent adhesion/migration signal-
ling remains incompletely understood. Several reports
have linked CD44 lipid raft affiliation to cell survival and
oncogenic signalling. CD44–hyaluronan interactions have
been suggested to take place in the lipid rafts of breast
cancer cells to facilitate oncogenic signalling [16], while
CD44 interactions with the cytoplasmic binding part-
ner merlin have been shown to inhibit cancer cell
growth [17].
Having recently shown that CD44 affiliation with lipid
rafts is reduced in migrating breast cancer cells and
hypothesised that translocation outside rafts permits cell
migration [18] we set out to examine whether dynamic
alterations in CD44 palmitoylation could directly drive
cell migratory events by modifying CD44 raft affiliation.
We show for the first time that manipulation of CD44
raft affiliation via site-directed mutagenesis of palmitoy-
lation sites influences the migration of invasive breast
cancer cells, and is sufficient to induce a motile pheno-
type and functions in non-invasive cells. Furthermore,
we demonstrate temporal reductions in palmitoylated
CD44 during stimulated migration of breast cancer cells.
Importantly, we provide evidence that reductions in
CD44 palmitoylation are paralleled by increased CD44
co-association with its binding partner ezrin. Our find-
ings in cell lines are supported by data from breast pri-
mary cell cultures, in which lower palmitoylation and
less co-localisation of CD44 with raft markers correlates
with more aggressive cancers. Our data are consistent
with a novel model whereby palmitoylation-induced re-
tention of CD44 within lipid rafts exerts a suppressive
effect on breast cancer cell migration. Post-translational
events of this nature offer a novel (non-genomic) possi-
bility to help explain the controversy that CD44 expres-
sion levels alone do not always correlate directly with
prognosis in different cancers. In conclusion, therefore,
we speculate that pharmacological targeting of CD44
palmitoylation may offer a fresh strategy to reduce cancer
cell dissemination during the early stages of metastasis.
Methods
Cell culture and transfection
Human breast cancer cell lines MCF-10a and MDA-
MB-231 were obtained from ATCC (LGC Standards,
Teddington UK). MDA-MB-231 cells were cultured in
Dulbecco’s modified Eagle’s medium (Sigma-Aldrich,
Arklow, Ireland) supplemented with 10% foetal bovine
serum, 2 mM L-glutamine, 100 U/ml penicillin and 100
μg/ml streptomycin. MCF-10a cells were cultured in
Dulbecco’s modified Eagle’s medium/F12 Ham (Sigma-
Aldrich) supplemented with 100 U/ml penicillin, 100
μg/ml streptomycin, 5% horse serum, 0.5 μg/ml hydro-
cortisone, 0.1 μg/ml cholera toxin, 10 μg/ml insulin and
20 ng/ml epidermal growth factor (all Sigma-Aldrich).
Mammary tumour primary cell cultures were generated as
described elsewhere [19] from mastectomies or lumpecto-
mies obtained with full consent and prior ethical approval
(Beaumont Hospital Medical Ethics (Research) Committee)
from symptomatic patients undergoing breast cancer
surgery in Beaumont Hospital. Primary cultures were
grown in mammary epithelial growth medium (Lonza,
Verviers, Belgium), prepared according to the manufac-
turer’s guidelines. For transient transfections (48 hours,
unless indicated otherwise) of plasmid DNA into the cells,
jetPRIME transfection reagent (Source Bioscience, Dublin,
Ireland) was used according to the manufacturer’s guide-
lines. Untransfected control cells were incubated with
DNA-diluting buffer alone. Transfected cells were selected
using chloramphenicol (Sigma-Aldrich) dissolved directly
in culture medium, at 300 μg/ml for MDA-MB-231 and at
500 μg/ml for MCF-10a, as determined by kill curve
proliferation assays (data not shown). Cells transfected
with wild-type CD44 acted as a conditional control. All
cells were cultured in a humidified incubator at 37°C and
5% carbon dioxide, and were confirmed to be mycoplasma
free by quarterly testing.
Antibodies and reagents
Mouse anti-human CD44 primary antibody, detecting all
isoforms of the protein, was obtained from R&D Systems
(Abingdon, UK) and used for western blot analysis.
For immunofluorescence and immunoprecipitation,
mouse CD44 antibody was purchased from Santa
Babina et al. Breast Cancer Research 2014, 16:R19 Page 2 of 14
http://breast-cancer-research.com/content/16/1/R19
Cruz Biotechnology (Heidelberg, Germany). Antibodies
to detect flotillin-1 and ezrin (mouse) were from BD
Biosciences (Oxford, UK). Mouse transferrin receptor
antibody and goat anti-rabbit horseradish peroxidase
(HRP) were from Cell Signaling Technologies (Danvers,
MA, USA). Antibodies against radixin, moesin, annexin II
and merlin (rabbit) were from GeneTex, Inc. (Irvine, CA,
USA). Rabbit flotillin-1 antibody (immunofluorescence),
anti-actin primary antibody and goat anti-mouse HRP sec-
ondary antibody were from Sigma-Aldrich. Streptavidin
HRP was from ThermoScientific (Ballycoolin, Ireland) and
Millipore (Cork, Ireland).
Plasmid constructs
A pOTB7 plasmid encoding wild-type human CD44
(imaGenes; Source Bioscience) was grown on Luria-
Bertani agar plates with 20 μg/ml chloramphenicol and
subsequently in Luria-Bertani broth with the same anti-
biotic concentration. Plasmid extraction was carried out
using Qiagen Midi-Prep kits following the manufacturer’s
protocols (Qiagen, Manchester, UK). This preparation was
used as template genetic material for site-directed muta-
genesis of CD44 palmitoylation sites. Single point muta-
tions were obtained using the QuikChange Site-Directed
Mutagenesis kit (Agilent Technologies Ireland Ltd, Cork,
Ireland). Cys286 was mutated to either serine (C286S) or
alanine (C286A). A double mutation was achieved using
the mutated Cys286 DNA as a template for introducing a
mutation at Cys295 to alanine. The mutagenesis primers
were obtained from Eurofins MWG Operon (Ebersberg,
Germany) and contained the sequences presented in
Table 1. All mutations were confirmed by sequencing of
the synthesised plasmids (Source Bioscience) and alignment
using BLAST software (National Institute of Health,
Bethesda, MD, USA). It is noteworthy that mammalian ex-
pression of pOTB7 plasmid inserts is normally achieved by
subcloning via the Gateway expression system (Life Tech-
nologies, Paisley, UK). However, based on the precedent
that mammalian expression can be successfully achieved
without the subcloning step [20] (albeit via an unknown
mechanism), we did not use the Gateway step.
Successful expression of the CD44 mutants in MDA-
MB-231 transfectants was confirmed by sequencing of
polymerase chain reaction products of reverse-transcribed
RNA using the following primers (5′ to 3′, codon under-
lined): C286A mutant (mutation of T-G at position 856),
forward GCAGATCGATTTGAATATAACCTGC and re-
verse CTGTTGACTGCAATGCCAACTG; and SA mu-
tant containing C286S and C295A mutations (mutation of
G-C at position 857 and TG-GC at positions 883 and
884), forward GCAGATCGATTTGAATATAACCTGC
and reverse GCTTTTTCTTCTGCCCAGCC. Polymer-
ase chain reaction product and sequencing results are
shown in Figure S1 in Additional file 1.
Triton X-100 insolubility assay
Cells were grown to confluence in six-well plates. Detergent-
soluble fractions (enriched in nonraft cellular components)
were obtained following 30 minutes of incubation at
4°C in lysis buffer (100 mM KCl, 3 mM NaCl, 3.5 mM
MgCl2, 10 mM HEPES) containing 1% Triton X-100
and protease and phosphatase inhibitor cocktails (Sigma-
Aldrich). The detergent-insoluble pool (enriched in lipid
rafts) was subsequently collected via scraping the wells
in one-half volume of lysis buffer. After determination
of protein concentrations using Bicinchoninic acid
assay, fractions of equivalent protein concentration
were analysed by immunoblotting.
Lipid raft extraction by discontinuous sucrose gradient
fractionation
All steps were carried out at 4°C. Cells were lysed in
calcium-positive and magnesium-positive Hank’s balanced
salts solution (Sigma-Aldrich) supplemented with 1% Triton
X-100 (Roche Diagnostics, West Sussex, UK) and a protease
inhibitor cocktail (Sigma-Aldrich). Lysates were dounced
×20 and triturated ×20 using a 26-gauge needle, and were
then mixed in a 1:1 ratio with 90% (w/v) sucrose (dissolved
in Hank’s solution). Then 4 ml was loaded into an ultracen-
trifuge tube (Roche Diagnostics) and sequentially overlain
with equal volumes of 30%, 20% and 5% (w/v) sucrose.
Preparations were ultracentrifuged in a Beckman Optima
L-100 K ultracentrifuge using an SW41Ti rotor (~260,000 ×
g/19 hours/4°C). One-millilitre fractions were collected
from the top and analysed as described previously [21].
Briefly, sucrose density was estimated using a refractom-
eter. Alkaline phosphatase activity, to identify lipid raft-
enriched fractions, was quantitated by incubating 1:10
volumes of fraction:p-nitrophenyl phosphate substrate
(Sigma-Aldrich) for 30 minutes, and measuring
absorbance at 405 nm. Additionally, each fraction was
tested for expression of lipid raft and nonraft markers
Table 1 Oligonucleotide primers used for site-directed
mutagenesis
Name Oligonucleotide (5′ to 3′)
C286A Forward GCT TTG ATT CTT GCA GTT GCC ATT GCA
GTC AAC AGT CG
C286A Reverse CGA CTG TTG ACT GCA ATG GCA ACT GCA
AGA ATC AAA GC
C286S Forward GCT TTG ATT CTT GCA GTT TCC ATT GCA
GTC AAC AGT CG
C286S Reverse CGA CTG TTG ACT GCA ATG GAA ACT
GCA AGA ATC AAA GC
C295A Forward CAG TCG AAG AAG GGC TGG GCA GAA
GAA AAA GC
C295A Reverse GCT TTT TCT TCT GCC CAG CCC TTC TTC
GAC TG
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Flotillin-1 and transferrin receptor (TfR), respectively,
using immuno-dot blot.
Immunoblotting
Equal protein concentrations were loaded onto 10%
Tris–HCl gels and subjected to SDS-PAGE. Protein was
transferred onto a nitrocellulose membrane by wet trans-
fer at 100 V/1 hour, incubated in blocking buffer (5% skim
milk or bovine serum albumin in TBS–0.1% Tween-20)
for 1 hour and incubated with primary antibody overnight
at 4°C. For dot blots, 2 μl each fraction was loaded directly
onto membranes, blocked, and incubated with primary
antibody overnight. After washing, membranes were
incubated with an appropriate HRP-conjugated sec-
ondary antibody for 1 hour at room temperature.
Membranes were developed by exposure to X-ray film
(Sigma-Aldrich) using enhanced chemiluminescent re-
agents (PerkinElmer Life Sciences, Waltham, MA, USA).
The same membranes were probed for expression of other
proteins via stripping primary antibody complexes with
0.7% 2-β-mercaptoethanol (Sigma-Aldrich) as described
previously [21].
Acyl-biotin exchange (1-biotinamido-4-(4′-(maleimidomethyl)
cyclohexanecarboxamido)butane assay)
This method was adapted from a previous publication [22].
Briefly, CD44 protein was immunoprecipitated from lysates
via overnight incubation at 4°C with 3 μg mouse anti-
human CD44 antibody as described elsewhere [18]. Anti-
body–protein complexes were collected by 3-hour rotation
at 4°C with 50 μg protein G-sepharose (Sigma-Aldrich), in
the presence of 50 mM N-ethylmaleimide (Sigma-Aldrich),
to covalently block sulfhydryl groups. Complexes were sub-
sequently divided into two fractions, for treatment with
and without 1 M hydroxylamine (Sigma-Aldrich) at room
temperature for 1 hour (pH 7.40) to cleave free palmitate
groups. Samples were then incubated with 1 μM EZ-link
biotin-1-biotinamido-4-(4′-(maleimidomethyl)cyclohexane-
carboxamido)butane (biotin-BMCC; ThermoScientific) at
pH 6.2 for 1 hour at room temperature, to label the reactive
cysteine residues. Labelled CD44 was released from the
beads via incubation (100°C/5 minutes) in 2× reducing
Lamelli sample buffer, and was subjected to SDS-PAGE
and immunoblotting. Biotin-BMCC-labelled CD44 was
detected with streptavidin-HRP, followed by antibody, to
visualise total CD44.
Scratch-wound migration assay
Confluent cells were subjected to ligand-independent
scratch-wound assays as described previously [18]. Briefly,
cells were wounded by a single scratch using a sterile
p200 pipette tip attached to suction, rinsed with
phosphate-buffered saline and allowed to migrate in
serum-free medium in a humidified incubator at 37°C/5%
carbon dioxide. Wells were imaged immediately after
wounding (time = 0) and the precise location subse-
quently photographed every 2 hours for 6 to 8 hours.
Wound widths were measured using Scion Image soft-
ware (Scion Corporation Ltd, Frederick, MD, USA) at
every time point, and the percentage wound closure was
calculated by expressing wound widths relative to the cog-
nate time = 0 measurement for each condition. Migration
versus time graphs were subsequently plotted using
SigmaPlot (Systat Software Inc, London, UK).
Image analysis and statistical analysis
Densitometric analysis was performed on western blot
films (exposed for equivalent times) using ImageJ soft-
ware (National Institute of Health, Bethesda, MD, USA).
Raw values were used for statistical analysis from a mini-
mum of three independent experiments, and averages
are expressed as the percentage of internal control (non-
migrating condition for untransfected cells, and CD44WT
for transfected cells). P values were calculated using equal
variance two-tailed Student’s t tests. For migration assays,
two-way analysis of variance tests were performed across
all time points using GraphPad Prism (GraphPad Soft-
ware, La Jolla, CA, USA). Results were considered signifi-
cant when P < 0.05.
Results
CD44 raft affiliation varies across differentially-invasive
breast cancer cells
We previously reported a decrease in CD44 lipid raft affili-
ation in migrating MDA-MB-231 and Hs578T cell lines
[18]. In the present study we firstly compared the raft affili-
ation status of CD44 in the non-invasive, normal-like cell
line MCF-10a and the highly-invasive cell line MDA-MB-
231. Isopycnic sucrose density gradient fractionation was
used to isolate rafts under migrating versus nonmigrating
conditions, and fractions were analysed for activity of the
raft-affiliated enzyme alkaline phosphatase. The enzyme
was most active in fractions 4 to 6 (Figure 1A), suggesting
enrichment of rafts at sucrose densities of 20 to 25%.
Immuno-dot blots (Figure 1B) confirmed partitioning of
the raft marker protein Flotillin-1 to the same fractions,
and exclusive detection of the nonraft marker TfR at higher
sucrose densities (Fractions 8 to 12; >30% sucrose). There-
after, we refer to fractions 4 to 6 as lipid raft fractions and
to fractions 9 to 11 as nonraft fractions.
Western blotting was used to compare the affiliation
of CD44 and its binding partners with rafts under non-
migrating and migrating conditions. In MCF-10a cells,
CD44 recovery in raft fractions was increased in migrating
versus nonmigrating cells (Figure 1C). A high molecular
weight CD44 band was also noted in raft fractions. Inte-
grated band densities from three independent experiments
were used to calculate the ratio of CD44 affiliation with
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lipid rafts (described previously [18]). This value (CD44
lipid raft:nonlipid raft) is CD44 normalised to Flotillin-1
as a loading control for raft fractions, divided by CD44
normalised to TfR as a loading control for nonraft frac-
tions. An increase in the ratio reflects increased CD44 raft
affiliation. In this study we concentrated on the standard
isoform of CD44, and this isoform alone was used for
estimation of the CD44 lipid raft:nonlipid raft ratio. A
significant increase in the ratio was noted in migrating
MCF-10a cells (Figure 1C, lower panel; P < 0.05). The
CD44 binding partners ezrin, radixin, moesin, merlin
and annexin II were detected only in nonraft fractions
(Figure 1C). In contrast to MCF-10a cells, CD44 recovery
in nonraft fractions of MDA-MB-231 cells was increased
after the induction of migration (Figure 1D). This was ac-
cordingly quantified as a significant decrease in the CD44
raft affiliation ratio (Figure 1D, lower panel; P < 0.05). Fur-
thermore, using isogenic cell line Hs578T and its more in-
vasive derivative Hs578Ts(i)8 [23], we observed a relatively
higher proportion of CD44 outside lipid rafts in the
Hs578Ts(i)8 cells (data not shown). As with MCF-10a, all
of the CD44 binding partners tested were recovered exclu-
sively from nonraft fractions in nonmigrating and migrat-
ing cells.
Figure 1 CD44 affiliation with lipid rafts is reduced during migration of highly-invasive breast cancer cells. Sucrose density gradient
fractionation was used to isolate lipid rafts from nonmigrating (a confluent cell monolayer) versus migrating (2 hours post scratch-wounding)
MDA-MB-231 cells. (A) Raft fractions were identified on the basis of peak biochemical activity of the lipid raft-affiliated enzyme alkaline phosphatase.
(B) Enrichment of the marker proteins Flotillin-1 (Flot-1) and transferrin receptor (TfR) by immuno-dot blot was further used to define the identity of
respectively raft versus nonraft fractions. (C) The western blot expression profile of CD44 and its binding partners in MCF-10a normal-like
breast cells revealed increased recovery of raft-affiliated CD44 after 2 hours of migration compared with nonmigrating controls. This was
verified by calculation of the raft affiliation ratio from the quantification of three independent experiments (histogram). The CD44 binding
partners tested were exclusively recovered from nonraft fractions. (D) CD44 recovery from lipid raft fractions of highly-invasive MDA-MB-231
breast cancer cells was reduced in migrating relative to nonmigrating conditions; and was paralleled by increased CD44 recovery from nonraft
fractions in migrating conditions. This observation was verified by calculation of the raft affiliation ratio from the quantification of three independent
experiments (histogram). The CD44 binding partners tested were exclusively recovered from nonraft fractions. Error bars, standard error of the
mean; n = 3 experiments. *P < 0.05, Student’s t test. NR, nonlipid raft; OD, optical density.
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CD44 palmitoylation-impaired mutants have reduced raft
affiliation
Having observed reduced CD44 raft affiliation in migrat-
ing highly invasive cells, we sought to directly manipu-
late CD44 raft affiliation to test its impact on cell
motility. Site-directed mutagenesis was used to intro-
duce point mutations into one (C286A or C286S) or
both (C286A,295A (AA) and C286S,295A (SA)) cysteine
residues that control CD44 palmitoylation and incorpor-
ation into rafts (Figure 2A). MDA-MB-231 cells were
transiently transfected with palmitoylation-impaired
CD44 constructs, negatively selected for 48 hours and
subjected to sucrose density gradient fractionation.
Whole cell lysate analysis by western blotting revealed
increased expression of CD44 in transfected cells
(Figure 2B), although we were not able to distinguish
between endogenous and exogenous protein. Raft and
nonraft fractions were identified by enrichment in respect-
ively Flotillin-1 and TfR (Figure 2C). Cells expressing
palmitoylation-impaired mutants had less CD44 in lipid
raft fractions and correspondingly more recovered
from nonraft domains. Compared with either CD44WT-
expressing or control cells, the CD44 raft affiliation ratio
was significantly reduced in cells expressing single or
double palmitoylation mutants (Figure 2D, P < 0.05).
Given the requirement for large quantities of material for
raft extraction preparations, Triton X-100 insolubility as-
says were investigated as a surrogate to estimate relative
amounts of CD44 in detergent-insoluble (putatively
raft-enriched) and detergent-soluble (putatively nonraft-
enriched) pools. As expected, Triton X-100-insoluble frac-
tions were enriched in Flotillin-1, while detergent-soluble
fractions were enriched in TfR (Figure 2E). MDA-MB-231
cells expressing wild-type CD44 had a similar CD44 solu-
bility/insolubility profile compared with control cells. In
contrast, cells transfected with CD44 palmitoylation mu-
tants showed decreased CD44 recovery in detergent-
insoluble pools and a corresponding increase in recovery
from detergent-soluble pools. Calculation of the affiliation
ratio of CD44 with detergent-insoluble fractions (‘CD44
Figure 2 CD44 palmitoylation-impaired constructs have reduced affiliation with lipid rafts. (A) Schematic representation of palmitoylation-impaired
CD44 constructs generated by site-directed mutagenesis of human CD44. Single-site mutants were termed C286A and C286S, while double-site mutants
(C286S + C295A, C286A + C295A) were termed SA and AA respectively. (B) MDA-MB-231 cells were transfected with full-length CD44 (CD44WT) or CD44
single-site (C286A, C286S) and double-site (SA, AA) palmitoylation-impaired mutants and were selected for 48 hours. Whole cell lysates revealed increased
expression of CD44 in the transfected cells. (C) Full-scale lipid raft extractions confirmed reductions in raft-affiliated CD44 in cells expressing
the mutant constructs relative to controls. (D) Calculation of the lipid raft:nonlipid raft (LR:NR) ratio for multiple experiments confirmed statistically
significant reductions in CD44 raft affiliation upon expression of the CD44 palmitoylation-impaired mutants. (E) Triton X-100-insoluble and Triton
X-100-soluble fractions were isolated and confirmed to be enriched in respectively lipid raft (Flotillin-1 (Flot-1)) or nonraft (transferrin receptor
(TfR)) markers. CD44 recovery from raft-enriched fractions was reduced in cells overexpressing mutant CD44, and paralleled by increased recovery of
CD44 in nonraft fractions. (F) Calculation of the affiliation ratio of CD44 with detergent-insoluble versus detergent-soluble fractions confirmed
reductions in raft-affiliated CD44 from cells expressing mutant constructs relative to controls. Error bars, standard error of the mean; n = 3. #P < 0.05
(C286S vs. control); *P < 0.05; **P < 0.01, Student’s t test. HAM, hydroxylamine; WT, wild-type.
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Insoluble:Soluble’, Figure 2F) revealed reductions in cells
expressing single or double palmitoylation mutants versus
control or CD44WT-overexpressing cells (P < 0.05 for
all). Since these findings mirrored results from sucrose
gradient raft extractions, the simpler detergent-extraction
approach was subsequently used.
Direct reduction of CD44 palmitoylation promotes a
migratory phenotype
To confirm that changes in CD44 raft distribution reflected
reductions in its palmitoylation, biotin-BMCC assays were
performed on nonmigrating cells overexpressing repre-
sentative single and double palmitoylation mutants
(Figure 3A,B). Free palmitate groups were cleaved from
CD44 immunoprecipitates using hydroxylamine, whereupon
reactive cysteines were labelled with biotin-BMCC and
detected with streptavidin. Biotin-labelled (palmitoylated)
CD44 was lower in cells expressing palmitoylation mu-
tants versus wild-type or control cells. Band quantitation
of palmitoylated versus total CD44 confirmed significant
reductions in palmitoylated CD44 in MDA-MB-231 cells
overexpressing single and double mutants (Figure 3B). To
determine whether forced exclusion of CD44 from rafts
directly promoted cell migration, scratch-wound assays
were performed in MDA-MB-231 cells transiently
transfected with CD44 palmitoylation-impaired mu-
tants (Figure 3C). Overexpression of CD44WT or CD44
single-site palmitoylation mutants doubled cell migration
compared with controls. Overexpression of CD44 double-
site palmitoylation mutants improved cell migration four-
fold relative to control cells (Figure 3C) or twofold relative
to CD44WT or single mutant cells (P < 0.05).
We next tested whether forced exclusion of CD44 from
rafts was sufficient to induce a migratory phenotype in
Figure 3 Reduced CD44 palmitoylation is paralleled by increased cell migration. (A) Biotin-1-biotinamido-4-(4′-(maleimidomethyl)
cyclohexanecarboxamido)butane (biotin-BMCC) assays were used to measure palmitoylated CD44 (CD44-Palm) in cells expressing representative
single and double palmitoylation mutants, and were compared with total CD44 levels (CD44-Total). Isotype-matched IgG was used as a negative
control for CD44 immunoprecipitations (IPs), and omission of hydroxylamine (HAM) reagent was a BMCC-negative control. CD44-Palm was
reduced in cells overexpressing CD44 palmitoylation-impaired mutant constructs. (B) Densitometric quantification of multiple experiments
confirmed significant reductions in CD44-Palm relative to CD44-Total in mutant cells. Error bars, standard error of the mean (SEM); n = 3. *P < 0.05; **P < 0.01,
Student’s t test. (C) Phase contrast micrographs of scratch-wound migration assays performed in MDA-MB-231 cells transfected for 48 hours with CD44WT or
CD44 single-site (C286A, C286S) or double-site (SA, AA) palmitoylation-impaired mutants. The graph was constructed by expressing wound
width measurements at each time point relative to its cognate time = 0 value. Cell migration was significantly enhanced in mutant-expressing cells
compared with control cells, as indicated in the graphical representation of multiple experiments. Error bars, SEM; n = 3. #φ*P < 0.05; **P < 0.01,
two-way analysis of variance. WT, wild-type.
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non-invasive breast cells. CD44 palmitoylation-impaired
mutants were overexpressed in histologically normal
MCF-10a cells, whereupon Triton X-100 insolubility
assays confirmed reduced partitioning to raft fractions
(Figure 4A). CD44 recovery in detergent-insoluble
pools was virtually abolished in cells expressing double-
site mutants (Figure 4B, P < 0.05 vs. CD44WT and P <
0.01 vs. control). Biotin-BMCC assays confirmed reduc-
tions in palmitoylated CD44 in cells overexpressing
CD44 palmitoylation-impaired mutants (Figure 4C,D).
Relative to control MCF-10a cells, overexpression of
either CD44WT or CD44 palmitoylation-impaired mu-
tants disrupted characteristically tight colonies in these
cells, inducing cell scattering in a manner reminiscent
of that reported to occur in epithelial-to-mesenchymal
transition (EMT; Figure 4E) in conjunction with re-
duced expression of the epithelial marker EpCAM and
enhanced expression of the mesenchymal marker
vimentin (Figure S2 in Additional file 2). This was ac-
companied by increased cell migration, particularly in
cells overexpressing CD44 double-site mutants (Figure 4F,
P < 0.05 vs. control). Mutant deselection after 48 hours
followed by two subcultures in normal medium normal-
ised both the CD44 raft affiliation ratio (Figure S3A,B,C,D
in Additional file 3) and cell migration (Figure S3E,F in
Additional file 3) to control levels.
Reduced CD44 palmitoylation facilitates ezrin binding
and correlates with invasive phenotype
Since modulation of CD44 palmitoylation reversibly modi-
fied cell migration, we questioned the reverse – whether
stimulation of cell migration might reduce CD44 palmi-
toylation to facilitate its extra-raft translocation. CD44
palmitoylation decreased in a statistically significant
manner during a migration time course (Figure 5A,B).
This was accompanied by a notable increase in CD44
co-precipitation with its pro-migratory binding partner
ezrin at 1 to 2 hours (Figure 5C). Similarly, CD44/ezrin
co-precipitation was increased in migrating cells ex-
pressing a CD44 double-site palmitoylation mutant
(Figure 5D).
Having shown a direct relationship between CD44 pal-
mitoylation status and cell migration, we translated this
into a more patient-relevant context by evaluating CD44
palmitoylation and raft affiliation status in representative
primary cultures isolated from non-invasive versus in-
vasive human breast tumours. Cultures derived from
non-invasive ductal carcinoma in situ tumours formed
organised colonies of luminal-like epithelial cells sur-
rounded by flattened, myoepithelial-like cells (Figure 5E,
phase contrast). Cultures derived from invasive ductal car-
cinoma tumours contained predominantly flattened pro-
trusive cells. CD44 co-localised extensively with Flotillin-1
in the cell membranes of ductal carcinoma in situ cultures
(Figure 5E), but there was little spatial overlap of these
proteins in invasive ductal carcinoma cultures. Accord-
ingly, lower levels of palmitoylated CD44 were detected in
whole cell extracts from six representative invasive ductal
carcinoma cultures relative to two representative nontu-
mour cultures (Figure 5F). Collectively, these results sug-
gest a novel clinical relevance for the regulation of
palmitoylation and lipid raft affiliation of CD44 in breast
cancer cells.
Discussion
Cell migration is an early molecular event in breast can-
cer metastasis, and identifying tumour markers that cor-
relate with metastatic potential is a focus of numerous
studies. CD44 has the ability to interact with numerous
components of the extracellular matrix, thereby facilitat-
ing cell migration and local invasion. CD44 has been de-
scribed previously as both a tumour suppressor [9] and
an oncoprotein [7] in various cancers, which highlights a
complex and probably tissue-specific role in oncogen-
esis. Despite expressional correlations of CD44 [24,25]
or its splice variants [7] with progression of aggressive
breast cancers, specific mechanisms of CD44-dependent
cell migration remain controversial. CD44 resides in
lipid rafts [6,26,27], organisation centres for molecules
that play key roles in cell migration and whose altered
functional behaviour has been implicated in diseases in-
cluding breast cancer [12]. We have shown that CD44
localisation in rafts limits associations with its cytoskel-
etal linker binding partner ezrin [18]. We therefore
hypothesised that translocation of CD44 outside rafts to
bind to migratory partners (such as ezrin) is a novel
regulatory mechanism controlling CD44-dependent cell
migration. In the present study we dissected the rela-
tionship between CD44 raft affiliation, ezrin association
and migratory potential in breast cancer cells.
Although hyaluronan has previously been used to
stimulate CD44-dependent migration [16,18,28], in this
study we concentrated on ligand-independent breast
cancer cell migration induced via scratch-wounding.
Having previously shown reduced CD44 raft affiliation
during migration of invasive MDA-MB-231 and Hs578T
breast cells [18], here we found that, in the normal-like
breast epithelial cell line MCF-10a, CD44 affiliation with
lipid rafts was in fact increased under migratory condi-
tions. This may suggest that lipid rafts sequester CD44
to limit the migration of normal-like cells. Accordingly,
the importance of lipid raft domains in maintaining
front–rear polarity during breast cancer cell migration
has been highlighted [29]. Also noteworthy is the exclu-
sive lipid raft recovery of what putatively are heavier
CD44 isoforms in MCF-10a cells. MCF-10a cells express
predominantly the CD44 standard isoform, but v8-10,
v3-10 and v2-10 mRNAs have also been detected [7].
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Since our focus was on the CD44 standard isoform, we
did not characterise which variants might be present in
our model. However, since changes in CD44 expression
during cell migration were observed only in lipid raft
fractions of this weakly motile cell line, it is tempting to
speculate that nonmalignant polarised cells sequester
proteins such as CD44 inside lipid rafts in order to limit
cell migration. In support of this hypothesis, heavier
CD44 isoforms have been reported in lipid rafts along
with CD44s and annexin II in the nontumorigenic breast
Figure 4 Reducing CD44 is sufficient to alter normal phenotype in breast cells. MCF-10a cells were transfected for 48 hours with full-length
CD44 (CD44WT), and single-site (C286A, C286S) or double-site (SA, AA) palmitoylation-impaired mutants. (A) Triton X-100-insoluble and Triton
X-100-soluble fractions were isolated, and were confirmed to be enriched in respectively lipid raft (Flotillin-1 (Flot-1)) and nonraft (transferrin
receptor (TfR)) marker proteins. Overexpression of mutant CD44 reduced CD44 recovery from raft-containing fractions compared with that
in untransfected controls and CD44WT-expressing cells. (B) Calculated ratios of CD44 affiliation with detergent-insoluble fractions reflected
significant reductions in CD44 raft affiliation in mutant cells compared with untransfected control cells, and furthermore in CD44 double-site
mutants compared with CD44WT. (C) CD44 palmitoylation was assessed by 1-biotinamido-4-(4′-(maleimidomethyl)cyclohexanecarboxa-
mido)butane (BMCC) assay in CD44 immunoprecipitates of control, CD44WT-expressing and CD44 mutant-expressing cells. Palmitoylated
CD44 was detected with streptavidin (CD44-Palm), and total CD44 detected using CD44 antibody (CD44-Total). No CD44 was immunopreci-
pitated in the isotype-matched IgG control lanes, and no palmitoylated CD44 was detected in the hydroxylamine (HAM)-negative control con-
ditions. In the HAM-positive condition, palmitoylated CD44 was reduced in mutant-expressing cells. (D) Quantification of palmitoylated CD44 (as a
ratio of total CD44) revealed significant reductions in cells overexpressing a double-site CD44 palmitoylation-impaired mutant (AA) relative to con-
trol or CD44WT-expressing cells (*P < 0.05; **P < 0.01, Student’s t test). (E) Phase-contrast micrographs 48 hours post transfection revealed a
change in the morphology of control MCF-10a colonies (Ctrl) following CD44 overexpression, with a protrusive, disseminated epithelial-to-
mesenchymal transition-like appearance in all of the CD44-overexpressing cells (arrows), which was particularly pronounced in those expressing the
CD44 palmitoylation-impaired mutants. (F) Migration was measured via scratch-wound assays, in which wound widths at each time point were
expressed relative to their cognate measurement at time = 0 for each condition. These assays revealed significant enhancements in the migratory cap-
acity of MCF-10a cells expressing CD44 palmitoylation-impaired mutants relative to control cells (*P < 0.05, two-way analysis of variance). Error bars,
standard error of the mean; n = 3 experiments. WT, wild-type.
Babina et al. Breast Cancer Research 2014, 16:R19 Page 9 of 14
http://breast-cancer-research.com/content/16/1/R19
Figure 5 Decreased CD44 palmitoylation is paralleled by increased co-association with ezrin. (A) CD44 immunoprecipitates from different
MDA-MB-231 migration time points were probed for palmitoylated CD44 by 1-biotinamido-4-(4′-(maleimidomethyl)cyclohexanecarboxamido)butane
(BMCC) assay. Palmitoylated CD44 was detected using streptavidin (CD44-Palm), and total CD44 detected using a CD44 primary antibody (CD44-Total).
The absence of hydroxylamine (HAM) treatment was a negative control for palmitoylated CD44. CD44-Palm levels decreased over the migration time
course. (B) Quantification of CD44-Palm as a ratio of CD44-Total revealed significant time-dependent reductions during migration. Error bars, standard
error of the mean; n = 3 experiments. *P < 0.05, Student’s t test. (C) CD44 was immunoprecipitated from whole cell lysates of MDA-MB-231 cells at the
indicated migration time points, with IgG as an internal control. Immunoprecipitates were probed for CD44 and ezrin, with the IgG heavy chain band in-
tensity considered as a loading control. Ezrin-CD44 co-immunoprecipitation (IP) was increased after 1 and 2 hours of cell migration compared with nonmi-
grating cells (time = 0). (D) CD44 was immunoprecipitated from migrating (2 hours) untransfected MDA-MB-231 (Ctrl), WT-expressing, single and
double palmitoylation mutant-expressing cells. The latter cells had a notable increase in CD44-ezrin co-association. IP experiments are representative of
three independent experiments. (E) Confluent breast primary cells were stained for CD44 (green) and Flotillin-1 (Flot-1, red). Nuclei were stained with
DAPI and are shown in grey. Ductal carcinoma in situ (DCIS) primary cells demonstrated the highest co-localisation of the two proteins compared with in-
vasive ductal carcinomas (IDC). (F) Whole cell lysates of primary cultures from two nontumour (NT), and six IDC of tumour grade 2 and 3 (three of each)
were subjected to BMCC assays to compare palmitoylated CD44 levels. Most palmitoylated CD44 (CD44-Palm) was recovered from NT cultures, while all
patient IDC cultures displayed comparatively little CD44-Palm. Palmitoylated CD44 levels densitometrically normalised to total CD44 (CD44-Total)
further demonstrated increased levels of CD44-Palm in NT samples. Error bars, standard deviation of duplicates in one experiment.
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epithelial cell line, EpH4 [30]. In view of intriguing evi-
dence that various CD44 isoforms may associate with
different histological parameters of breast cancer [7], it
will be interesting to probe the relative raft/nonraft ex-
pression of these variants in response to cell migration
in future studies.
In contrast to MCF-10a cells, CD44 lipid raft affili-
ation in the metastatic cell line MDA-MB-231 was al-
most halved during cell migration. Additionally, we
observed a lower content of CD44 in nonraft fractions
of Hs578T cells relative to that in its more invasive iso-
genic derivative Hs578Ts(i)8 (data not shown). These ob-
servations support our hypothesis of a direct relationship
between increased extra-raft localisation of CD44 and a
more invasive/migratory breast cancer cell phenotype. To
our knowledge, these are the first reports of a link be-
tween CD44 raft localisation and breast cancer cell mi-
gration. However, localisation of CD44 outside lipid
rafts in human glioblastoma cells has been shown to
induce metalloproteinase-mediated CD44 shedding and
tumour cell migration [31], which was further confirmed
after membrane cholesterol modulation with methyl-β-
cyclodextrin, filipin and simvastatin [32]. In contrast, raft
affiliation of CD44 has been demonstrated to recruit Src
and integrins in gastric and colorectal cancers, promoting
cell survival and increasing endothelial adhesion [33]. Pre-
vious reports from the Isacke group have suggested that
alterations in cell motility do not alter CD44 associations
with detergent-insoluble cellular pools [11]. However,
under their experimental conditions, random, nondi-
rectional migration/spreading was induced in subcon-
fluent cells in response to scatter factor, whereas our
conditions induced directional cell migration in fully
confluent cells via ligand-independent wound closure
methodologies. Any perceived discrepancies between
the studies are thus likely to be context dependent, but
we speculate that CD44 redistribution outside rafts is
associated with directional motility while perhaps be-
ing less important for random motility. The potential
implications of this for cell migration out of an in vivo
tumour are significant, but are not well understood. It
is intriguing to speculate that our directional cell mi-
gration model might recapitulate the phenomenon of
Indian file collective cell migration out of certain primary
breast tumours; while nondirectional models of cell mi-
gration might mimic that of single-cell amoeboid-like mi-
gration out of primary tumours. That said, our findings
vis-à-vis the association between extra-raft CD44 and in-
vasion/migration are broadly supported by data in primary
cultures from breast cancer patients. This represents an
important pathophysiological context that cannot be repli-
cated in immortalised cell cultures. Taken together, our
overall data in breast cells suggest that CD44 localisation
outside lipid rafts is associated with a pro-migratory state;
furthermore, a range of CD44 binding partners was only
ever recovered from nonraft domains. Given the reported
involvement of ezrin [34] and ankyrin [35] in cancer pro-
gression and of merlin in tumour suppression [17], we
speculate that the spatial availability of CD44 to interact
with specific cytosolic partners may differentially regulate
cancer cell migration.
Dual acylation of two cysteine residues (Cys286 and
Cys295) in the CD44 transmembrane region has been
shown to be required for its raft association in fibro-
blasts and embryonic kidney cells [36]. We thus used
transient overexpression of palmitoylation-impaired mu-
tants as a tool to decrease CD44 affiliation with lipid
rafts. Triton X-100 insolubility assays were used as a sur-
rogate for lipid raft extractions, since detergent-insoluble
fractions have been shown to be enriched in lipid
rafts [32,37]. Overexpression of CD44 palmitoylation-
impaired mutants reduced the affiliation of CD44
with rafts, but CD44WT-overexpressing cells also
presented decreased CD44 raft affiliation. This may
reflect enhanced CD44 trafficking, since we observed
a coincident increase in vesicular/cytoplasmic stain-
ing of an early endosomal marker in CD44WT cells
(data not shown). It is also noteworthy that raft affili-
ation of total CD44, encompassing the endogenous
pool in addition to the exogenously expressed pool,
appeared to be reduced upon expression of CD44WT
or CD44 mutants. Although the mechanism whereby
endogenous CD44 might accordingly reduce its affili-
ation with rafts is unknown, one speculation is that it
reflects hetero-dimerisation between endogenous and
overexpressed CD44 and their consequent co-trafficking
in/out of rafts. However, Neame and colleagues have pre-
viously shown that transfected CD44 does not associate
with endogenous CD44 [11]. Nevertheless, CD44 has been
shown to homo-dimerise on activated leukocytes via
Cys286 [38] and to hetero-dimerise with growth factor re-
ceptors [39]. Since point mutation of Cys286 in our ex-
perimental system might reduce potential dimerisation
events, a possible alternative is that the overexpression of
wild-type or mutant CD44 simply exerts a negative tone
on the overall expression of endogenous CD44. While this
could be tested by incorporating specific tags onto en-
dogenous CD44 versus exogenous CD44, the fact that the
tags might themselves influence raft/nonraft partitioning
[40] complicates the clarity of both question and answer.
Nonetheless, despite only using a transient transfection
approach featuring very modest levels of CD44 overex-
pression, the important point is that distinct functional
differences were observed in MDA-MB-231 cells as a dir-
ect consequence of reduced CD44 raft affiliation. Specific-
ally, migration was higher in cells expressing CD44
palmitoylation mutants relative to controls or CD44WT-
expressing cells. It is also noteworthy that higher cell
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migration in CD44WT versus control cells was paralleled
by lower levels of palmitoylated CD44 in the former. The
published links between CD44WT overexpression and cell
migration/invasion in breast cancer cell lines [41] and pa-
tient samples [14] may thus also reflect a proportional de-
crease in CD44 palmitoylation status.
Our data have also revealed that forcing CD44 outside
lipid rafts with palmitoylation mutants was sufficient to
enhance cell migration and to induce an appearance
reminiscent of EMT in histologically normal MCF-10a
breast cells. Cells overexpressing CD44WT also acquired
some morphological features of EMT (in terms of a
more scattered/migratory phenotype), but over a longer
time course. Although we did not quantitate cell scatter-
ing or extensively characterise the relative phenotypes of
mutants versus controls, our morphological observations
are consistent with studies showing decreased epithelial
markers and increased mesenchymal markers upon
CD44 activation [42], and links between CD44, EMT
and breast cancer progression [42]. That our observed
effects related specifically to CD44 mutant expression was
confirmed upon termination of selection. Furthermore,
this served as an isogenic control for the inevitable differ-
ences in CD44 expression that occur between separate cell
lines. Such expressional differences were evident in
HMEC, MCF7 and BT-474 breast cells (all of which were
tested in addition to the ones discussed in this report),
and which accordingly complicated the generation of a
single paradigm relating CD44 raft/nonraft affiliation to
migration across all cell lines. Interestingly, EMT in MCF-
10a cells has been linked to a switch between a high mo-
lecular weight CD44 isoform and the standard isoform
[42]. It is unknown where this transition should take
place; however, we noted reduced expression of high mo-
lecular weight CD44 in palmitoylation mutant cells. Fur-
thermore, CD44 localisation in lipid rafts and levels of
palmitoylation in nontumour versus invasive breast cancer
primary cultures supports the conclusions we have made
in normal-like versus highly invasive breast cancer cell
lines. Taken together, this might suggest that, in the early
stages of cancer progression, the standard form of CD44
becomes prevalent and localises outside lipid rafts in order
to bind its oncogenic binding partners and stimulate cell
migration.
Figure 6 Schematic representation of the proposed model of regulation of breast cancer cell migration via CD44 localisation in lipid
rafts. When CD44 is affiliated with lipid rafts via palmitoylation of its cysteine residues, it is sequestered from binding its cytoplasmic binding
partners and thus migration is restrained. However, when CD44 translocates outside lipid rafts in its de-palmitoylated state, its cytoplasmic tail is
free to bind its cytoskeletal partners, subsequently facilitating cell migration. ERM, Ezrin/Radixin/Moesin.
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Having shown that CD44 palmitoylation inversely reg-
ulates cell migration, we sought to examine whether mi-
gration itself might alter CD44 palmitoylation. We present
novel evidence that CD44 palmitoylation is temporally re-
duced during breast cancer cell migration. Although the
mechanisms for this reduction remain elusive, it is
possible that actin rearrangements during migration
facilitate altered spatial access of palmitoylating or
de-palmitoylating enzymes to targets such as CD44.
More importantly, reductions in CD44 palmitoylation
were paralleled by enhanced co-association of CD44
with the linker protein ezrin, providing a direct mech-
anism for cytoskeletal engagement in order to drive
cell migration. The potential clinical significance of
this observation was illustrated by the fact that CD44
palmitoylation levels were low in primary cultures
from human invasive ductal carcinomas in compari-
son with nontumour tissue; and that co-localisation
of CD44 with the lipid raft marker Flotillin-1 was also
low in invasive specimens. We are therefore confident
that changes in CD44 raft affiliation via palmitoyla-
tion alterations is not an artefact of in vitro manipula-
tions, but rather a physiological phenomenon that
merits further investigation.
Conclusion
Our findings are consistent with a novel model in which
CD44 palmitoylation facilitates its sequestration within
lipid rafts, restricting its availability to bind to pro-
migratory binding partners such as ezrin (Figure 6) and
thereby restraining tumourigenic behaviour. We submit
that further studies into mechanisms underlying the
regulation of CD44 palmitoylation and lipid raft contain-
ment may merit evaluation as a novel target to reduce
breast cancer metastatic spread.
Additional files
Additional file 1: is Figure S1 showing transfected CD44 DNA
expression was confirmed in MDA-MB-231 cells. (A) DNA from
MDA-MB-231 cells transfected with CD44 mutants C286A and
C286S,295A (SA) in a pOTB7 vector and selected with chloramphenicol
was extracted, polymerase chain reaction (PCR)-amplified using
primers specific to C286A (lane 2) and SA (lane 3) and 100 ng purified
product separated on a 1% agarose gel. The probable presence of mutant
CD44 in MDA-MB-231 cells (in the appropriate size ranges) was confirmed,
while the negative control lane (no template DNA) remained blank.
(B) Successful expression of both the C286A and SA mutants in transfected
MDA-MB-231 cells was confirmed by sequencing of the purified PCR
products (50 ng).
Additional file 2: is Figure S2 showing overexpression of CD44 or
its palmitoylation-impaired mutants induces an EMT-like state.
MCF-10a cells were transfected for 48 hours with CD44WT, single-site
(C286A) or double-site (AA) palmitoylation-impaired mutant constructs.
Immunoblotting for the epithelial marker EpCAM and the mesenchymal
marker vimentin suggested an EMT-like switch in cells overexpressing
CD44WT or its palmitoylation mutants.
Additional file 3: is Figure S3 showing biochemical and functional
phenotypes in cells overexpressing CD44 palmitoylation-impaired
mutants are reversible. Following 48-hour expression of CD44WT or
palmitoylation-impaired single (C268A, C286S) or double (SA, AA) mutants
in MDA-MB-231 and MCF-10a cells, the cells were subcultured and grown
without selection reagent for a further 48 hours. (A) After termination of
CD44WT or mutant selection in MCF-10a cells, CD44 recovery from Triton
X-100-insoluble fractions was restored to match that of control cells. (B)
Lack of statistically-significant differences (ns, not significant, Student’s t test)
between the raft affiliation ratio of CD44 in control MCF-10a cells, versus
those in which mutant selection had been terminated, confirmed
restoration of a normal biochemical phenotype. (C) Scratch-wound
assays confirmed that cell migration returned to control levels in
MCF-10A cells following termination of expression of CD44WT or
palmitoylation-impaired mutants (two-way analysis of variance
(ANOVA)). (D) After termination of CD44WT or mutant selection in
MDA-MB-231 cells, CD44 recovery from Triton X-100-insoluble fractions
was restored to match that of control cells (ns, not significant, Student’s t test).
(E) Scratch-wound assays confirmed that cell migration returned to control
levels in MDA-MB-231 cells following termination of expression of CD44WT
or palmitoylation-impaired mutants (two-way ANOVA). Error bars, standard
error of the mean; n = 3 experiments.
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